FOLH1 and neoplasm: While significantly higher PSA response rates were observed with [177Lu]Lu-PSMA-617 versus cabazitaxel (66% vs. 37%, p < 0.0001), high FDG metabolic tumour volume (MTV ≥ 200 mL) was associated with poorer outcomes across arms on post-hoc analysis, suggesting the FDG-high cohort may require more intensive treatment strategies [6, 32].